Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. This will, in fact, prove to be an especially busy one for us, since we will be ensconced in a day-long industry gathering. So posting today may be a bit spotty. Of course, breaking away from the trusty laptop can be a good thing, now and then. And we will be all eyes and ears as we practice our hobnobbing. Meanwhile, here are a few items of interest to help you on your own journey. Hope your day is productive and we look forward to catching up….

Merck (MRK) raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including its top-selling Keytruda cancer treatment, Reuters reports. The list price increases are the first that the company made since pledging in July that it would not raise the average net price of all of its medicines by more than the inflation rate. A Merck spokeswoman says the average net price, including rebates and discounts, fell 1.9 percent in the U.S. last year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Since there is no transparency on “all [Merck] medicines.” how shall we rate the truth of this statement. “A Merck spokeswoman says the average net price, including rebates and discounts, fell 1.9 percent in the U.S. last year.”
    For clarity it ranks with, “to the best of my recollection” – if below “I cannot recall, Senator.”

Comments are closed.